Therefore, we hypothesized that CpG island HLA-G DNA methylation profile in peripheral blood cells may provide putative useful non-invasive predictive biomarkers and drug targets, which may improve CHD precision medicine and personalized therapy [17–19]. This evidence concerns the gene HLA-G and coronary artery disorder.